New therapies for chronic hepatitis B. (Q38725759)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26854115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

review article

1 reference

title

New therapies for chronic hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26854115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26854115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Maya Bitton Alaluf

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26854115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

14 March 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26854115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26854115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26854115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26854115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

775-782

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26854115%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus infection--natural history and clinical consequences

7 March 2020

cites work

1 reference

21 January 2018

Hepatocellular carcinoma

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

21 January 2018

1 reference

Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.

21 January 2018

1 reference

Review article: current antiviral therapy of chronic hepatitis B.

21 January 2018

1 reference

Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment

21 January 2018

1 reference

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities

21 January 2018

1 reference

Chronic hepatitis B: what should be the goal for new therapies?

21 January 2018

1 reference

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Chronic hepatitis B: A wave of new therapies on the horizon

21 January 2018

1 reference

Present and future therapies of hepatitis B: From discovery to cure

21 January 2018

1 reference

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

21 January 2018

1 reference

Inhibition of hepatitis B virus in mice by RNA interference

21 January 2018

1 reference

Inhibition of hepatitis B virus expression and replication by RNA interference

21 January 2018

1 reference

RNA interference--small RNAs effectively fight viral hepatitis

21 January 2018

1 reference

Core protein: A pleiotropic keystone in the HBV lifecycle

21 January 2018

1 reference

Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids

21 January 2018

1 reference

A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly

21 January 2018

1 reference

High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein

21 January 2018

1 reference

The hepatitis B virus ribonuclease H as a drug target

21 January 2018

1 reference

Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

21 January 2018

1 reference

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

21 January 2018

1 reference

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

21 January 2018

1 reference

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.

21 January 2018

1 reference

Inhibitors of hepatitis B virus attachment and entry

21 January 2018

1 reference

Strategies to inhibit entry of HBV and HDV into hepatocytes.

21 January 2018

1 reference

Host-virus interactions in hepatitis B virus infection.

21 January 2018

1 reference

Early inhibition of hepatocyte innate responses by hepatitis B virus.

21 January 2018

1 reference

Genomic analysis of the host response to hepatitis B virus infection

21 January 2018

1 reference

HBV and the immune response

21 January 2018

1 reference

Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

21 January 2018

1 reference

Pathogen recognition receptors: ligands and signaling pathways by Toll-like receptors

21 January 2018

1 reference

Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B

21 January 2018

1 reference

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

Structural mechanism of cytosolic DNA sensing by cGAS

21 January 2018

1 reference

STING agonists induce an innate antiviral immune response against hepatitis B virus

21 January 2018

1 reference

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

21 January 2018

1 reference

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection

21 January 2018

1 reference

Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA.

21 January 2018

1 reference

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

21 January 2018

1 reference

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study

21 January 2018

1 reference

Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.

21 January 2018

1 reference

Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.

21 January 2018

1 reference

Coinhibitory receptors and CD8 T cell exhaustion in chronic infections

21 January 2018

1 reference

PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.

21 January 2018

1 reference

Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection

21 January 2018

1 reference

Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir

21 January 2018

1 reference

Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection

21 January 2018

1 reference

Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses

21 January 2018

1 reference

Does Tyrosyl DNA Phosphodiesterase-2 Play a Role in Hepatitis B Virus Genome Repair?

21 January 2018

1 reference

CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity

21 January 2018

1 reference

Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease

21 January 2018

1 reference

The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo

21 January 2018

1 reference

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

21 January 2018

1 reference

Targeting Hepatitis B Virus With CRISPR/Cas9.

21 January 2018

1 reference

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

21 January 2018

1 reference

In vivo genome editing using Staphylococcus aureus Cas9

21 January 2018

1 reference

Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation

21 January 2018

1 reference

Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation

21 January 2018

1 reference

Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells.

21 January 2018

1 reference

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

21 January 2018

1 reference

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

21 January 2018

1 reference

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.13086

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26854115%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference